{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:20:28Z","timestamp":1778044828806,"version":"3.51.4"},"reference-count":148,"publisher":"Elsevier","isbn-type":[{"value":"9780443241147","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmbts.2024.05.001","type":"book-chapter","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:02:36Z","timestamp":1715806956000},"page":"23-58","source":"Crossref","is-referenced-by-count":4,"title":["Drug repurposing for parasitic protozoan diseases"],"prefix":"10.1016","member":"78","reference":[{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspectives"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/bs.pmbts.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2174\/1568026616666160216154309","article-title":"Neglected tropical protozoan diseases: drug repositioning as a rational option","volume":"16","author":"Laura Sbaraglini","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17460441.2016.1195945","article-title":"Drug target identification in protozoan parasites","volume":"11","author":"M\u00fcller","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejmech.2014.10.057","article-title":"A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity","volume":"89","author":"Moine","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2042-7158.2010.01205.x","article-title":"Synthesis and antimalarial activity of ethylene glycol oligomeric ethers of artemisinin","volume":"63","author":"Steyn","year":"2011","journal-title":"J Pharm Pharmacol"},{"issue":"25","key":"10.1016\/bs.pmbts.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug\u2010combinations for infectious diseases.","volume":"175","author":"Zheng","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/bs.pmbts.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/molecules25153409","article-title":"Repurposing drugs to fight hepatic malaria parasites","volume":"25","author":"Fontinha","year":"2020","journal-title":"Molecules"},{"issue":"9859","key":"10.1016\/bs.pmbts.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib18","series-title":"Working to Overcome the Global Impact of Neglected Tropical Diseases: First Who Report on Neglected Tropical Diseases","year":"2010"},{"issue":"9814","key":"10.1016\/bs.pmbts.2024.05.001_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","article-title":"Global malaria mortality between 1980 and 2010: a systematic analysis","volume":"379","author":"Murray","year":"2012","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib20","first-page":"277","article-title":"Neglected parasitic infections: what family physicians need to know \u2013 a CDC update","volume":"104","author":"Cantey","year":"2021","journal-title":"Am Fam Phys"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/B978-0-12-407704-1.00007-5","article-title":"New approaches for the identification of drug targets in protozoan parasites","volume":"301","author":"M\u00fcller","year":"2013","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874104501105010001","article-title":"Drug development to protozoan diseases","volume":"5","author":"Monzote","year":"2011","journal-title":"Open Med Chem J"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib23","series-title":"The Global Burden of Disease: 2004 Update","author":"Mathers","year":"2008"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.3390\/molecules26082304","article-title":"Drug repurposing: a review of old and new antibiotics for the treatment of malaria: identifying antibiotics with a fast onset of antiplasmodial action","volume":"26","author":"Pessanha De Carvalho","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12936-022-04178-7","article-title":"Reflections on the 2021 World Malaria Report and the future of malaria control","volume":"21","author":"Monroe","year":"2022","journal-title":"Malaria J"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","article-title":"The past, present and future of anti-malarial medicines","volume":"18","author":"Tse","year":"2019","journal-title":"Malaria J"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","article-title":"Current and emerging strategies to combat antimalarial resistance","volume":"20","author":"Rasmussen","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol Res"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib29","unstructured":"World Health, O., Fact sheet 340 Chagas disease (American Trypanosomiasis). http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en (accessed May 4, 2015)."},{"key":"10.1016\/bs.pmbts.2024.05.001_bib30","article-title":"Drug repurposing for Leishmaniasis with hyperbolic graph neural networks","author":"Lau","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-4-86","article-title":"LeishVet guidelines for the practical management of canine leishmaniosis","volume":"4","author":"Solano-Gallego","year":"2011","journal-title":"Parasit Vectors"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"issue":"30","key":"10.1016\/bs.pmbts.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"20539","DOI":"10.2807\/1560-7917.ES2013.18.30.20539","article-title":"Epidemiological surveillance of leishmaniasis in the European Union: operational and research challenges","volume":"18","author":"Gradoni","year":"2013","journal-title":"Eurosurveillance"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"R770","DOI":"10.1016\/j.cub.2018.05.035","article-title":"Toxoplasma gondii","volume":"28","author":"Kochanowsky","year":"2018","journal-title":"Curr Biol"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib36","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/pharmaceutics14081634","article-title":"Drug repurposing based on protozoan proteome: in vitro evaluation of in silico screened compounds against Toxoplasma gondii","volume":"14","author":"Cajazeiro","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib37","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acsinfecdis.8b00113","article-title":"Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro","volume":"4","author":"Radke","year":"2018","journal-title":"ACS Infectious Diseases"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3201\/eid0901.020160","article-title":"Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil","volume":"9","author":"Bahia-Oliveira","year":"2003","journal-title":"Emerging Infectious Diseases"},{"issue":"5\u20106","key":"10.1016\/bs.pmbts.2024.05.001_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0463.2009.02453.x","article-title":"Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence","volume":"117","author":"Blader","year":"2009","journal-title":"Apmis"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/microorganisms9122531","article-title":"Toxoplasmosis: current and emerging parasite druggable targets","volume":"9","author":"Hajj","year":"2021","journal-title":"Microorganisms"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00325481.2019.1655258","article-title":"Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis","volume":"131","author":"Lapinskas","year":"2019","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/9781608058648115010004","article-title":"Knowledge-based drug repurposing: a rational approach towards the identification of novel medical applications of known drugs","author":"Bellera","year":"2015","journal-title":"Front. Comput Chem"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.carres.2003.09.038","article-title":"Data mining the protein data bank: automatic detection and assignment of carbohydrate structures","volume":"339","author":"L\u00fctteke","year":"2004","journal-title":"Carbohydr Res"},{"issue":"D1","key":"10.1016\/bs.pmbts.2024.05.001_bib45","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.05.001_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079568","article-title":"SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery","volume":"8","author":"Novick","year":"2013","journal-title":"PloS one"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib47","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1021\/ci400155x","article-title":"Relating anatomical therapeutic indications by the ensemble similarity of drug sets","volume":"53","author":"Wu","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by ligand chemistry","volume":"25","author":"Keiser","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"7270","key":"10.1016\/bs.pmbts.2024.05.001_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.1976.25.14","article-title":"Single-dose therapy of Falciparum malaria using pyrimethamine in combination with diformyldapsone or sulfadoxine","volume":"25","author":"Doberstyn","year":"1976","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-6-45","article-title":"Evidence from bioinformatics, expression and inhibition studies of phosphoinositide-3 kinase signalling in Giardia intestinalis","volume":"6","author":"Cox","year":"2006","journal-title":"BMC Microbiol"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib52","unstructured":"Wei C-P , Chen , K-A, Chen L-C. Mining biomedical literature and ontologies for drug repositioning discovery. In: Advances in Knowledge Discovery and Data Mining: 18th Pacific-Asia Conference, PAKDD 2014, Tainan, Taiwan, May 13\u201316, 2014. Proceedings, Part II 18. 2014. Springer."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib53","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0735-1097(86)80232-7","article-title":"Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms","volume":"7","author":"Haedo","year":"1986","journal-title":"J. Am Coll Cardiol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib54","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cell.2011.02.016","article-title":"Interactome networks and human disease","volume":"144","author":"Vidal","year":"2011","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.abb.2013.12.023","article-title":"Minocycline inhibits angiogenesis in vitro through the translational suppression of HIF-1\u03b1","volume":"545","author":"Jung","year":"2014","journal-title":"Arch Biochem Biophys"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib56","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1128\/AAC.33.12.2144","article-title":"Tetracyclines as antiparasitic agents: lipophilic derivatives are highly active against Giardia lamblia in vitro","volume":"33","author":"Edlind","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"Chong","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"22","key":"10.1016\/bs.pmbts.2024.05.001_bib58","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1073\/pnas.1118370109","article-title":"Liver-stage malaria parasites vulnerable to diverse chemical scaffolds","volume":"109","author":"Derbyshire","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"6043","key":"10.1016\/bs.pmbts.2024.05.001_bib59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1126\/science.1205216","article-title":"Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets","volume":"333","author":"Yuan","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/00313029500169742","article-title":"Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage","volume":"27","author":"Bird","year":"1995","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/amiajnl-2013-001700","article-title":"Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds","volume":"21","author":"Sateriale","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1747-0285.2006.00389.x","article-title":"Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei","volume":"67","author":"Mackey","year":"2006","journal-title":"Chem Biol Drug Des"},{"issue":"5795","key":"10.1016\/bs.pmbts.2024.05.001_bib63","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib64","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","article-title":"Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials","volume":"71","author":"K\u00f6hler","year":"2014","journal-title":"JAMA psychiatry"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.05.001_bib65","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jphp.12815","article-title":"Drug repurposing may generate novel approaches to treating depression","volume":"69","author":"Ebada","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib66","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1741-7015-11-200","article-title":"So depression is an inflammatory disease, but where does the inflammation come from?","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4269\/ajtmh.2006.74.401","article-title":"Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study","volume":"74","author":"Miller","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","article-title":"Paromomycin: uptake and resistance in Leishmania donovani","volume":"164","author":"Jhingran","year":"2009","journal-title":"Mol Biochem Parasitol"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.05.001_bib70","first-page":"1401","article-title":"German coloring agent which became the current sulfa","volume":"90","author":"Hakulinen","year":"1993","journal-title":"Lakartidningen"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.05.001_bib71","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4155\/fmc.11.95","article-title":"Drug repositioning in the treatment of malaria and TB","volume":"3","author":"Nzila","year":"2011","journal-title":"Future Med Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jac\/dkl104","article-title":"The past, present and future of antifolates in the treatment of Plasmodium falciparum infection","volume":"57","author":"Nzila","year":"2006","journal-title":"J Antimicrobial Chemother"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib73","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically available medicines demonstrating anti-Toxoplasma activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib74","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.38.3.570","article-title":"Rifabutin is active in murine models of toxoplasmosis","volume":"38","author":"Araujo","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","article-title":"Pharmacologic and clinical evaluation of posaconazole","volume":"8","author":"Moore","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.05.001_bib76","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0166-6851(81)90047-5","article-title":"Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi","volume":"3","author":"Docampo","year":"1981","journal-title":"Mol Biochem Parasitol"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-6851(02)00280-3","article-title":"Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa","volume":"126","author":"Roberts","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib79","first-page":"415","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/642502","article-title":"Sterol biosynthesis pathway as target for anti-trypanosomatid drugs","volume":"2009","author":"de Souza","year":"2009","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib82","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull World Health Organ"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib83","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa011882","article-title":"Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major","volume":"346","author":"Alrajhi","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083247","article-title":"In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis","volume":"8","author":"de Macedo-Silva","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib85","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/314782","article-title":"Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action","volume":"179","author":"Buates","year":"1999","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.05.001_bib86","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/429238","article-title":"Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru","volume":"40","author":"Miranda-Ver\u00e1stegui","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/ph15020128","article-title":"Discovery, development, inventions and patent review of fexinidazole: the first all-oral therapy for Human African Trypanosomiasis","volume":"15","author":"Imran","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2013a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00436-010-1906-y","article-title":"In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani","volume":"107","author":"Zhang","year":"2010","journal-title":"Parasitol Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib90","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.actatropica.2013.09.018","article-title":"Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in Leishmania (L.) infantum","volume":"128","author":"Mesquita","year":"2013","journal-title":"Acta Tropica"},{"issue":"19","key":"10.1016\/bs.pmbts.2024.05.001_bib91","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1021\/jm3007596","article-title":"Salicylanilide inhibitors of Toxoplasma gondii","volume":"55","author":"Fomovska","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib92","first-page":"475","article-title":"Effect of an 8-aminoquinoline on albino rats experimentally infected with Trypanosoma cruzi.(Preliminary note)","volume":"60","author":"de Lucena","year":"1961","journal-title":"Hospital (Rio de Janeiro, Brazil)"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/parasite\/2011182115","article-title":"Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance","volume":"18","author":"Loiseau","year":"2011","journal-title":"Parasite: Journal de la Soci\u00e9t\u00e9 Fran\u00e7aise de Parasitologie"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1472-8206.2003.00167.x","article-title":"Treatment perspectives for human African trypanosomiasis","volume":"17","author":"Bouteille","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib95","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib96","first-page":"218","article-title":"Methotrexate in the therapy of malaria","volume":"30","author":"Wildbolz","year":"1973","journal-title":"Ther Umsch, Rev Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib97","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jama.1970.03180010051011","article-title":"Methotrexate therapy for Plasmodium vivax malaria","volume":"214","author":"Sheehy","year":"1970","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/bs.pmbts.2024.05.001_bib98","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib99","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.48.3.852-859.2004","article-title":"Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes","volume":"48","author":"Paris","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.05.001_bib100","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.4049\/jimmunol.0803859","article-title":"Miltefosine promotes IFN-\u03b3-dominated anti-leishmanial immune response","volume":"182","author":"Wadhone","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14656566.2013.755515","article-title":"Leishmaniasis: an update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.05.001_bib102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbapap.2005.08.018","article-title":"Protein kinases as drug targets in trypanosomes and Leishmania","volume":"1754","author":"Naula","year":"2005","journal-title":"Biochim Biophys Acta (BBA) \u2013 Proteins Proteomics"},{"issue":"14","key":"10.1016\/bs.pmbts.2024.05.001_bib103","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1074\/jbc.M511504200","article-title":"An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei","volume":"281","author":"Tu","year":"2006","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib104","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2958.2009.06657.x","article-title":"The cell cycle as a therapeutic target against Trypanosoma brucei: hesperadin inhibits Aurora kinase\u20101 and blocks mitotic progression in bloodstream forms","volume":"72","author":"Jetton","year":"2009","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/157.1.14","article-title":"In vitro assessment of antimicrobial agents against Toxoplasma gondii","volume":"157","author":"Harris","year":"1988","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib106","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/jm970090r","article-title":"1, 4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma","volume":"41","author":"Christensen","year":"1998","journal-title":"J Med Chem"},{"issue":"3-4","key":"10.1016\/bs.pmbts.2024.05.001_bib107","first-page":"61","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov Today: Ther Strategies"},{"issue":"690","key":"10.1016\/bs.pmbts.2024.05.001_bib108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/pgmj.59.690.229","article-title":"Efficacy and side effects of mianserin, a tetracyclic antidepressant","volume":"59","author":"Wakeling","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.exppara.2014.06.004","article-title":"Mianserin, an antidepressant kills Leishmania donovani by depleting ergosterol levels","volume":"144","author":"Dinesh","year":"2014","journal-title":"Exp Parasitol"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib110","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00436-014-3868-y","article-title":"Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani","volume":"113","author":"Singh","year":"2014","journal-title":"Parasitol Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib111","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1128\/AAC.00522-07","article-title":"Oral therapy with amlodipine and lacidipine, 1, 4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis","volume":"52","author":"Palit","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.05.001_bib112","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.bbamem.2016.06.010","article-title":"Statin-induced chronic cholesterol depletion inhibits Leishmania donovani infection: relevance of optimum host membrane cholesterol","volume":"1858","author":"Kumar","year":"2016","journal-title":"Biochim Biophys Acta (BBA)-Biomembranes"},{"key":"10.1016\/bs.pmbts.2024.05.001_bib113","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1007\/s00436-015-4618-5","article-title":"Antileishmanial effect of mevastatin is due to interference with sterol metabolism","volume":"114","author":"Dinesh","year":"2015","journal-title":"Parasitol Res"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.05.001_bib114","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: pharmacological re\u2010engagement with a neglected disease","volume":"152","author":"Barrett","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"36","key":"10.1016\/bs.pmbts.2024.05.001_bib115","doi-asserted-by":"crossref","first-page":"33930","DOI":"10.1074\/jbc.M103950200","article-title":"Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase","volume":"276","author":"Montalvetti","year":"2001","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib116","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm0002578","article-title":"Bisphosphonates inhibit the growth of Trypanosoma b rucei, Trypanosoma c ruzi, Leishmania d onovani, Toxoplasma g ondii, and Plasmodium f alciparum: a potential route to chemotherapy","volume":"44","author":"Martin","year":"2001","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijantimicag.2003.07.020","article-title":"Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi","volume":"23","author":"Garzoni","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib118","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bmcl.2006.11.004","article-title":"Identification of the benzodiazepines as a new class of antileishmanial agent","volume":"17","author":"Clark","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1211\/jpp.61.03.0017","article-title":"Metabolism of two new benzodiazepine-type anti-leishmanial agents in rat hepatocytes and hepatic microsomes and their interaction with glutathione in macrophages","volume":"61","author":"Thi","year":"2009","journal-title":"J Pharm Pharmacol"},{"issue":"3-4","key":"10.1016\/bs.pmbts.2024.05.001_bib120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1515\/znc-2016-0129","article-title":"Synthesis and biological evaluation of newer 1, 3, 4-oxadiazoles incorporated with benzothiazepine and benzodiazepine moieties","volume":"72","author":"Navin","year":"2017","journal-title":"Zeitschrift f\u00fcr Naturforschung C"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.05.001_bib121","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1021\/jm500131s","article-title":"Multitarget drug discovery for tuberculosis and other infectious diseases","volume":"57","author":"Li","year":"2014","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.05.001_bib122","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1128\/AAC.03972-14","article-title":"SQ109, a new drug lead for Chagas disease","volume":"59","author":"Veiga-Santos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"27","key":"10.1016\/bs.pmbts.2024.05.001_bib123","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1002\/chem.201200482","article-title":"Parasite\u2010based screening and proteome profiling reveal orlistat, an FDA\u2010approved drug, as a potential anti Trypanosoma brucei agent","volume":"18","author":"Yang","year":"2012","journal-title":"Chem A Eur\u00a0J"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib124","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjmed.2018.08.025","article-title":"The computerized ECG: friend and foe","volume":"132","author":"Smulyan","year":"2019","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1124\/jpet.300.1.195","article-title":"Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone","volume":"300","author":"Courchesne","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib126","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/jm050691f","article-title":"Amiodarone has intrinsic anti-trypanosoma c ruzi activity and acts synergistically with posaconazole","volume":"49","author":"Benaim","year":"2006","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.05.001_bib127","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.01215-08","article-title":"Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.05.001_bib128","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/AAC.01240-13","article-title":"Dronedarone, an amiodarone analog with improved anti-Leishmania mexicana efficacy","volume":"58","author":"Benaim","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.05.001_bib129","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00207-12","article-title":"In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile","volume":"56","author":"Benaim","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib130","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.01544-06","article-title":"Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth","volume":"51","author":"Mishina","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijantimicag.2010.03.008","article-title":"Efficacy of artemisinin in experimental visceral leishmaniasis","volume":"36","author":"Sen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.05.001_bib132","article-title":"Free radical metabolism of antiparasitic agents","volume":"45","author":"Docampo","year":"1986","journal-title":"Fed Proc"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.05.001_bib133","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/AAC.00505-09","article-title":"Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib134","first-page":"29","article-title":"Cotrimoxazole for childhood febrile illness in Malaria-endemic regions","volume":"8","author":"Bloland","year":"1992","journal-title":"Malawi Med J"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4269\/ajtmh.2006.75.375","article-title":"Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)\u2013infected persons on the selection of sulfadoxine-pyrimethamine\u2013resistant malaria parasites among HIV-uninfected household members","volume":"75","author":"Malamba","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.05.001_bib136","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.mph.0000212994.56812.f2","article-title":"Antitumor activity of nifurtimox observed in a patient with neuroblastoma","volume":"28","author":"Saulnier Sholler","year":"2006","journal-title":"J Pediatr Hematol\/Oncol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MPH.0b013e3181f47061","article-title":"A phase 1 study of nifurtimox in patients with relapsed\/refractory neuroblastoma","volume":"33","author":"Saulnier Sholler","year":"2011","journal-title":"J Pediatr Hematol\/Oncol"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.05.001_bib138","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archderm.1991.01680060108015","article-title":"Treatment of cutaneous sarcoidosis with chloroquine: review of the literature","volume":"127","author":"Zic","year":"1991","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib139","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.05.001_bib140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00126334-200403010-00002","article-title":"Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors","volume":"35","author":"Savarino","year":"2004","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib141","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2008.06.005","article-title":"Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection","volume":"378","author":"Brouwers","year":"2008","journal-title":"Virology"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.05.001_bib142","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AAC.46.5.1163-1173.2002","article-title":"Antiparasitic agent atovaquone","volume":"46","author":"Baggish","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.05.001_bib143","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.35.2.293","article-title":"Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii","volume":"35","author":"Araujo","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"4703","key":"10.1016\/bs.pmbts.2024.05.001_bib144","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (artemisinin): an antimalarial drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.05.001_bib145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","article-title":"Artemisinins: their growing importance in medicine","volume":"29","author":"Krishna","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.05.001_bib146","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543776.2012.724063","article-title":"Artemisinin derivatives: a patent review (2006\u2013present)","volume":"22","author":"Njuguna","year":"2012","journal-title":"Expert Opin Ther Pat"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.05.001_bib147","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.05.001_bib148","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14787210.2.1.43","article-title":"Nitazoxanide: a new broad spectrum antiparasitic agent","volume":"2","author":"White","year":"2004","journal-title":"Expert Rev Anti-Infect Ther"}],"container-title":["Progress in Molecular Biology and Translational Science","Clinical Application of Repurposed Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:13:16Z","timestamp":1753355596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117324000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443241147"],"references-count":148,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.05.001","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}